ArticleJournal of gastrointestinal oncology2026
Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy in non-metastatic pancreatic ductal adenocarcinoma (PDAC) is increasingly being studied and used in clinical practice. However, this strategy is associated with significant toxicity, biopsy-related and biliary complications and possible treatment delay. We aimed to assess the feasible number of cycles of neoadjuvant (modified) FOLFIRINOX and the real-world toxicity, to inform an optimal interventional trial design. Methods: In this descriptive monocentric study, we identified patients with borderline resectable or locally advanced PDAC, treated with upfront (m)FOLFIRINOX from 2020 to 2023. We analyzed patient and disease characteristics, dosing of therapy, occurrence of serious adverse events (SAEs) and reasons for discontinuation, and compared this data with available evidence in the literature. Results: Eighty-one patients were included. Median age was 65, most patients had an ECOG performance status of 0. 62.5% of tumors were borderline resectable, the others were locally advanced. 49 patients (60.5%) received mFOLFIRINOX, 32 (39.5%) received FOLFIRINOX and the median number of cycles administered was six. Most common reasons for discontinuation were surgery (n=45, 55.6%) and persistently inoperable or progressive disease (n=25, 30.9%), with toxicity accounting for a much smaller proportion (n=5, 6.2%). Global dose intensities gradually decreased over time. Dose reduction was necessary in 43 patients (53%), and 37 patients (45.7%) needed inpatient care. However, supportive care measures allowed most patients to overcome toxicity and finish the planned treatment cycles. Conclusions: With adequate supportive care and dose modifications, the majority of patients were able to complete the assigned chemotherapy cycles. Eight cycles of mFOLFIRINOX appear feasible for most patients and may serve as an optimal regimen for evaluation in future interventional trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.